Taxotere + Cisplatin in Nasopharyngeal Carcinoma

• Status: Completed
• Trial end date: 2010-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary objective:

To assess and compare the toxicities of patients with advanced NPC treated with concurrent cisplatin-radiotherapy with or without neoadjuvant Taxotere (docetaxel) and cisplatin.

Secondary objective:

To assess tumor control and survival

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sanofi
• Treatments: Cisplatin; Docetaxel

Criteria

Inclusion Criteria:

• International Union against Cancer stages III and IV newly diagnosed NPC

Exclusion Criteria:

• Inadequate bone marrow reserve

• Inadequate renal function

• Other primary malignancy

• Evidence of distant metastases

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.